Xeris Biopharma Holdings, Inc. provided revenue guidance for the year 2024. The company anticipates 2024 total revenue to grow from 2023 levels.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.88 USD | -0.79% | +7.43% | -20.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.00% | 281M | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+19.59% | 323B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Year 2024